The Blood and Marrow Transplant Program at Northside Hospital is a collaboration between The Blood and marrow Transplant Group of Georgia (BMTGA) and Northside Hospital.
For the Third Consecutive Year, NSH-BMT has the BEST Survival Outcomes in the Country for Allogeneic and Unrelated Donor Transplants
[READ MORE]
*Transplant Centers must have performed ten or greater allogeneic transplants annually.
NSH-BMT Patient Asa Valente Meets Her Unrelated Donor at the
2012 BeTheMatch Tribute Dinner
On September 22, 2012, Asa Valente, a NSH-BMT patient who received primary leukemia treatment and an unrelated donor transplant in 2011, met her British donor, Edward Collier, at the 2012 BeTheMatch Tribute Dinner. Edward is a medical student who became involved in blood/marrow donor donation through a donor drive held at his medical school, Imperial College in London, England. Through his selfless generosity, Edward has given Asa a gift of a healthy and bright future.
Please click here to read more of Asa’s story,by Michelle Hiskey, or visit at Saportareport.com.
National Marrow Donor Program (NMDP): Post Transplant Mobile App is Now Available
To help physicians with the reference materials they need to care for transplant patients, the NMDP has developed an app with leading transplant organizations to help increase survival rates. For more information, please go to Post BMT Discharge Instructions.
NSH-BMT Featured on WSB-TV Atlanta- People 2 People: Northside Hospital Sponsors BeTheMatch® Donor Drive
NSH-BMT Featured on WSB-TV Atlanta: Why More African-American Donors Needed for Life Saving Treatment for Blood Disorders
NSH-BMT Now Enrolling Patients to Three Innovative Clinical Trials:
NSH IRB 952- Relapsed B-Cell Non-Hodgkin Lymphoma Post CHOP-R
A randomized, multicenter study comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in patients with aggressive B-Cell non-hodgkin lymphoma, who have relapsed after therapy with CHOP-R or an equivalent regimen and are ineligible for stem cell transplant.
NSH IRB 959- Allogeneic Transplantation for Patients with HIV Infection
Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals
NSH IRB 988- Double Cord vs Haploidentical Transplantation
A multi-center, phase III, randomized trial of reduced intensity conditioning (RIC) and transplantation of double unrelated umbilical cord (I corrected lingo from draft website) versus HLA-haploidentical related donor bone marrow for patients with hematologic malignancies.
Please call Stacey Brown at 404-851-8238 to inquire about study details and eligibility requirements.
Join the Fight Against Cancer
By donating platelets and blood you can join the fight and directly impact the healthcare of patients being treated at NSH-BMT/Leukemia by donating with Atlanta Blood Services. To donate or find out additional information please go to http://www.atlantabloodservices.com/index.htm Or Click here to Like ABS on Facebook: http://www.facebook.com/atlantabloodservices
NSH-BMT Program Named as Core Clinical Transplant Center
NSH-BMT is the only transplant program in Georgia to receive the prestigious designation of Core Clinical Center from the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN). This designation is accompanied by a research grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI). The Program is one of 20 out of more than 120 such BMT Programs in the United States to be awarded this status.
NSH-BMT's Commitment to BeTheMatch Registry®
Dr. Solomon Presents at Prestigious 2011 Annual ASH Meeting Press Program
Dr. Scott Solomon, ASH abstract, Haploidentical Transplantation Using T-Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of a Prospective Phase II Trial [Abstract 889], was one of only four abstracts chosen to present at the Improving Recovery and Survival Strategies for Patients Who Undergo Transplantation ASH Press Program. This presentation platform allowed Dr. Solomon to review his innovative and cutting edge clinical research to national and international attendees. The Press Program was also attended by various media outlets. Please read Dr. Solomon�s ASH press release and featured article in Oncology Times, February 25, 2012- Volume 34- Issue 4 � p 32-5, Oncology-Times.com.
BMTGA Participates in Quality Oncology Practice Initiative, (QOPI)
BMTGA is proud to announce their continued commitment to quality service, by participating in the Quality Oncology Practice Initiative (QOPI), an affiliate of the American Society of Clinical Oncology (ASCO). Currently, BMTGA is the first hematopoietic blood and marrow transplant program in the state of Georgia to participate in this rigorous quality assessment.
QOPI is a voluntary, self-assessment and improvement program launched by ASCO in 2006 to help hematology and oncology practices assess the quality of the care they provide to patients. QOPI analyzes the individual practice data, focused on process and structure, not outcome, and compares this to evidence-based guidelines and consensus-based quality measures.
The Blood and Marrow Transplant Program at Northside Hospital (NSH-BMT) provides the best of both worlds � clinical excellence and compassionate care. Committed to being the premier program in the Southeast, we provide outstanding state-of-the-art care for patients with leukemia and for those patients undergoing blood marrow and stem cell transplantation.